The Federal Circuit’s recent decision to uphold a Patent Trial and Appeal Board ruling that dietary supplement patents licensed by Merck KGaA are invalid as obvious illustrates the many risks for patents in inter partes reviews as well as the difficulty of overturning PTAB decisions on appeal.
The Federal Circuit's affirmance also provides a clear picture of the deference that the appeals court is giving the board in AIA reviews on factual issues like secondary considerations.
IP associate David Soofian noted that given such findings are subject to deference on appeal, they will be harder to overturn, adding in that “the standard of review can make or break a case."
Also of Interest
- Benchmark Litigation Recognizes Kaye Scholer Practices and Partners Nationwide October 24, 2016 • Recognitions
- Maier Plans Emergency Response with Fort Meade and Fort Detrick Commanders October 20, 2016 • Client Successes
- Winning the War: Strategies for Prevailing in Consumer Fraud and False Advertising... October 17, 2016 • Articles
- Consumer Products in the Age of Big Data October 4, 2016 • Articles
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- UNITED STATES: Trade Facilitation and Trade Enforcement Act of 2015 Strengthens... August 23, 2016 • Articles
- UNITED STATES: Phantom Mark Depicting Arrangement of Numerical Financial Data... August 23, 2016 • Articles